Responses
E-Posters
E-Poster Viewing
EPV279/#351 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline brca mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.